GlassScriptPhysician profile
Susan M Monohan
NPI 1700819729
$4,161.15
in general payments reported to CMS, 2019-2025
39 companies · $829 in 2025
The $829 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $83.30 · 2021: $302 · 2022: $597 · 2023: $846 · 2024: $938 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,600.94 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $753.11 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $581.86 | 2019-2025 | |
| Novo Nordisk INC | $455.80 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $328.90 | 2019-2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $235.21 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $189.13 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.25 | 2019-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.28 | 2019-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.51 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $111.33 | 2019-2025 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $94.61 | 2022-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $88.25 | 2019-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Abbott Laboratories | $81.32 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $80.70 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $68.24 | 2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Monohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.